Escient Pharmaceuticals
Latest round
- Series C
Last raised
- Nov 2022
Total raised
- $109M
Investors
- 14
About Escient Pharmaceuticals
Established in 2018 by co-founders Alain D. Baron and Marcus F. Boehm and based in California, US, Escient Pharmaceuticals, Inc. focuses on G protein-coupled receptors drugs (MRGPRs) for the treatment of serious diseases including chronic urticaria, atopic dermatitis, asthma, and severe pruritus. In April 2024, Incyte Corporation agreed to acquire Escient Pharmaceuticals, Inc. from Abingworth, Forge Life Science Partners, New Enterprise Associates, Avego, PFM Health Sciences, The Eleven Fund, Altitude Life Science Ventures, Cowen Investment Management, OUP (Osage University Partners), Redmile Group, Sanofi Ventures, The Column Group, 5AM Venture, and Perceptive Advisors for USD 750 million. Escient Pharmaceuticals' pipeline includes EP262 and EP547. EP262 is an MRGPRX2 antagonist that targets conditions like chronic inducible urticaria (CIndU), chronic spontaneous urticaria (CSU), and atopic dermatitis (AD). EP262 is designed to inhibit the activity of the MRGPRX2 receptor, which is implicated in these dermatological conditions. By blocking this receptor, EP262 reduces the symptoms and improves the quality of life for patients suffering from these chronic conditions. EP547 (MRGPRX4 Antagonist): This addresses cholestatic pruritus (CP) and uremic pruritus (UP). EP547 targets the MRGPRX4 receptor in pruritic conditions associated with liver and kidney diseases. Additionally, Escient is conducting ongoing research into other Mrgprs, including MRGPRD and MRGPRX1, in the discovery stage.
Who invested in Escient Pharmaceuticals
14 investors across 3 rounds
See all investors in Escient Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Escient Pharmaceuticals
Who invested in Escient Pharmaceuticals?
Escient Pharmaceuticals has 14 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Escient Pharmaceuticals raised?
Escient Pharmaceuticals has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Escient Pharmaceuticals last raise money?
Escient Pharmaceuticals's most recent round on record is a Series C, in Nov 2022.
What does Escient Pharmaceuticals do?
Established in 2018 by co-founders Alain D.
Where is Escient Pharmaceuticals headquartered?
Escient Pharmaceuticals is headquartered in San Diego, US.
Which VCs invest in companies like Escient Pharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Escient Pharmaceuticals's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Escient Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.